Notice of Extension of the Expiration Date of PAR-18-654 "Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)"
Notice Number:
NOT-CA-20-089

Key Dates

Release Date:
July 29, 2020

Related Announcements

PAR-18-654 - Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to extend the expiration date of PAR-18-654, “Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)" by one Application Due Date.

Therefore, with the addition/extension by one Application Due Date of February 8, 2021, PAR-18-654 will now expire on February 9, 2021.

The following sections in Part 1. Overview Information, Key Dates, have been changed:

Currently reads:

Application Due Date(s): June 19, 2018; November 19, 2018; June 18, 2019; November 19, 2019; June 18, 2020; November 19, 2020

Corrected to read (in italics):

Application Due Date(s): June 19, 2018; November 19, 2018; June 18, 2019; November 19, 2019; June 18, 2020; November 19, 2020; February 8, 2021.

Currently reads:

Scientific Merit Review: November 2018; March 2019; November 2019; March 2020; November 2020; March 2021

Corrected to read (in italics):

Scientific Merit Review: November 2018; March 2019; November 2019; March 2020; November 2020; March 2021; June 2021

Currently reads:

Advisory Council Review: January 2019; May 2019; January 2020; May 2020; January 2021; May 2021

Corrected to read (in italics):

Advisory Council Review: January 2019; May 2019; January 2020; May 2020; January 2021; May 2021; August 2021

Currently reads:

Earliest Start Date: April 2019; July 2019; April, 2020; July 2020; April 2021; July 2021

Corrected to read (in italics):

Earliest Start Date: April 2019; July 2019; April, 2020; July 2020; April 2021; July 2021; November 2021

Currently reads:

Expiration Date: November 20, 2020

Corrected to read (in italics):

 Expiration Date: February 9, 2021

All other aspects of PAR-18-654 remain unchanged.

Inquiries

Please direct all inquiries to:

Tiffany Wallace, Ph.D.
National Cancer Institute (NCI)
Telephone:240-276-5114
Email: [email protected]


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices